Federated Hermes Inc. Has $29.41 Million Stake in Guardant Health, Inc. (NASDAQ:GH)

Federated Hermes Inc. increased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 11.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 962,722 shares of the company's stock after buying an additional 99,072 shares during the quarter. Federated Hermes Inc. owned 0.78% of Guardant Health worth $29,411,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GH. R Squared Ltd bought a new stake in shares of Guardant Health during the fourth quarter worth $26,000. SBI Securities Co. Ltd. bought a new position in Guardant Health during the 4th quarter worth about $43,000. Kimelman & Baird LLC bought a new position in Guardant Health during the 4th quarter worth about $58,000. Quantbot Technologies LP acquired a new stake in shares of Guardant Health in the 4th quarter valued at about $80,000. Finally, Jones Financial Companies Lllp raised its position in Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after buying an additional 817 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Piper Sandler boosted their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Mizuho initiated coverage on Guardant Health in a report on Thursday. They set an "outperform" rating and a $55.00 price target for the company. Raymond James restated an "outperform" rating and set a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. The Goldman Sachs Group boosted their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Barclays dropped their price objective on shares of Guardant Health from $60.00 to $55.00 and set an "overweight" rating for the company in a research note on Thursday. Twenty equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Guardant Health presently has a consensus rating of "Buy" and a consensus price target of $49.00.

Remove Ads

Guardant Health Price Performance

GH stock traded up $1.78 during midday trading on Monday, reaching $45.49. 355,805 shares of the stock were exchanged, compared to its average volume of 2,135,945. The stock has a market capitalization of $5.61 billion, a PE ratio of -12.78 and a beta of 1.45. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The company has a fifty day moving average price of $43.57 and a 200 day moving average price of $35.78.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.